Please ensure Javascript is enabled for purposes of website accessibility

GoodRx Q4 Update: Solid Growth, Weak Guidance

By Keith Speights - Mar 12, 2021 at 6:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Prescription transaction volume fueled strong revenue growth for the healthcare company in Q4.

Is GoodRx Holdings (GDRX -8.20%) stock a buy? It's looked like a pretty good pick so far this year. The stock was up around 8% as of the market close on Thursday.

However, the company announced its fourth-quarter results after the market closed on Thursday. The healthcare stock fell 4% in after-hours trading. Here are the highlights from GoodRx's Q4 update.

Hundred dollar bill in prescription bottle.

Image source: Getty Images.

By the numbers

GoodRx reported revenue in the fourth quarter of $153.5 million. This reflected a 36% increase from the prior-year period revenue total of $113.3 million. The consensus among Wall Street analysts projected Q4 revenue of $147.8 million.

How did GoodRx's bottom line look in the fourth quarter? The company reported a net loss of $298.3 million, or $0.74 per share, based on generally accepted accounting principles (GAAP). This compared to net income of $15.2 million, or $0.04 per share, in the same period in 2019. 

The company's adjusted net income in the fourth quarter totaled $32.2 million, or $0.08 per share. This was an increase from GoodRx's adjusted earnings of $23 million, or $0.06 per share, in the prior-year period. It was also better than the consensus analysts' adjusted earnings estimate of $0.07 per share.

Behind the numbers

GoodRx's strong revenue growth in the fourth quarter was driven primarily by higher prescription transaction volume. The company reported Q4 prescription transaction revenue of $131.3 million, up 26% year over year. Monthly active consumers jumped 32% year over year despite continuing COVID-19 headwinds. 

The company's prescription transaction revenue increase could have been even higher. GoodRx noted that it experienced a very weak cold and flu season. 

Other revenue soared 153% year over year to $22.2 million. This figure included growth from rebates from drug manufacturers and telehealth services. 

With such an impressive top-line performance, why did GoodRx's GAAP bottom line deteriorate? The company recorded a $296.7 million increase in stock-based compensation expense and payroll tax expense. In addition, GoodRx had a $41.7 million non-cash non-recurring charge. 

Looking ahead

GoodRx anticipates that revenue for the first quarter of 2021 will be between $158 million and $161 million. This reflects close to 20% year-over-year growth at the midpoint of the range, but it was a little lower than anticipated. The company also expects that the full year 2021 revenue will fall between $735 million and $755 million, an increase of around 35%.

Co-CEOs Doug Hirsch and Trevor Bezdek said that the company sees 2021 as a "massive opportunity to bring more value to our consumers at each stage of their healthcare journey." They also added that GoodRx "remain[s] intently focused on continuing to strengthen our brand and broaden our reach, taking our content and insights to the next level, and investing in our platform to launch new products and services."

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

GoodRx Holdings, Inc. Stock Quote
GoodRx Holdings, Inc.
GDRX
$8.17 (-8.20%) $0.73

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
345%
 
S&P 500 Returns
119%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.